A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

US biopharmaceuticals giant Gilead has thrown its weight behind a potential merger of Ireland’s Poolbeg Pharma and Austria ...

TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...

Wesley Sundquist’s lab laid foundation for development of a highly effective, long-lasting preventive measure against HIV.

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...

GS-2121 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...

CWA Asset Management Group LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.5% in ...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $91.41, denoting a -0.51% change from the preceding trading day.

Fortunately, my home isn't too far from Stamford Bridge stadium, making it easy to catch the action live! Connect with Peter ...

Roughly 61,000 Georgians live with HIV, the sexually transmitted virus (STI) that can lead to AIDS, and Atlanta ranks in the ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...